Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2009-12-24

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm901543mPMID 19891491PMCID PMC2825141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigenetics in cancer.

  2010cited by this paper
• A chemiluminescence-based method for identification of histone lysine methyltransferase inhibitors.

  2010cited by this paper
• Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294

  2009cited by this paper
• Cancer treatment of the future: inhibitors of histone methyltransferases.

  2009cited by this paper
• Epigenetics in cancer.

  2008cited by this paper
• Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells

  2008cited by this paper
• Role of histone modifications in defining chromatin structure and function

  2008cited by this paper
• Chemical probes for histone-modifying enzymes.

  2008cited by this paper
• Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

  2007cited by this paper
• Chromatin‐modifying proteins in cancer

  2007cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• L3MBTL1 recognition of mono- and dimethylated histones

  2007cited by this paper
• The mammalian epigenome.

  2007cited by this paper
• Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state.

  2006cited by this paper
• DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.

  2005cited by this paper
• Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9

  2005cited by this paper
• A coupled fluorescent assay for histone methyltransferases.

  2005cited by this paper
• The diverse functions of histone lysine methylation

  2005cited by this paper
• Translating the Histone Code

  2001cited by this paper
• The language of covalent histone modifications

  2000cited by this paper
• Regulation of chromatin structure by site-specific histone H3 methyltransferases

  2000cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• Discovery of 2-tetrahydroisoquinoline substituted quinazoline derivatives as lysine methyltransferase G9a inhibitors with in vivo antitumor efficacy.

  2025cites this paper
• Small molecule compounds targeting G9a/GLP: Recent advances and perspectives.

  2025cites this paper
• Effect of Histone Lysine Methyltransferase G9a Inhibitor on Lifespan and Radioresistance in Drosophila melanogaster

  2025cites this paper
• Epigenetic targets and their inhibitors in the treatment of idiopathic pulmonary fibrosis.

  2025cites this paper
• Targeting Histone H3K9 Methyltransferase G9a as a Potential Therapeutic Strategy for Neuropsychiatric Disorders

  2025cites this paper
• Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy.

  2025cites this paper
• G9a/GLP Modulators: Inhibitors to Degraders.

  2025cites this paper
• A Novel PROTAC G9a/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation.

  2025cites this paper
• Identification, validation, and characterization of approved and investigational drugs interfering with the SARS‐CoV‐2 endoribonuclease Nsp15

  2025cites this paper
• Chromatin Regulatory Targets for Anticancer Therapeutics.

  2025cites this paper
• Bromodomain-Driven Regulation of Stem Cells: A Potential Target for Cancer Therapeutic Intervention

  2025cites this paper
• G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials

  2025cites this paper
• Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.

  2025cites this paper
• Targeting the epigenome with advanced delivery strategies for epigenetic modulators

  2024cites this paper
• Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.

  2024cites this paper
• GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms

  2024cites this paper
• Lysine and arginine methylation of transcription factors

  2024cites this paper
• SETDB1 as a cancer target: challenges and perspectives in drug design.

  2024cites this paper
• Quinoline-based compounds can inhibit diverse enzymes that act on DNA.

  2024cites this paper
• Roles of Lysine Methylation in Glucose and Lipid Metabolism: Functions, Regulatory Mechanisms, and Therapeutic Implications

  2024cites this paper
• Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.

  2024cites this paper
• Synthetic Approaches to Dimeric and Oligomeric Hexahydropyrrolo[2,3-b]indole Alkaloids.

  2024cites this paper
• Discovery of the First-in-Class G9a/GLP PROTAC Degrader.

  2024cites this paper
• Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.

  2024cites this paper
• G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications

  2024influential citation
• Synthesis of diversely substituted quinazoline-2,4(1H,3H)-diones by cyclization of tert-butyl (2-cyanoaryl)carbamates.

  2024cites this paper
• Discovery of the First-in-class G9a/GLP PROTAC Degrader

  2024cites this paper
• Current and Emerging Approaches Targeting G9a for the Treatment of Various Diseases.

  2024cites this paper
• Integration of ligand and structure-based pharmacophore screening for the identification of novel natural leads against Euchromatic histone lysine methyltransferase 2 (EHMT2/G9a)

  2023influential citation
• Anti-babesial activity of a series of 6,7-dimethoxyquinazoline-2,4-diamines (DMQDAs).

  2023cites this paper
• Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.

  2023cites this paper
• Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies.

  2023cites this paper
• MSCs as Tumor-Specific Vectors for the Delivery of Anticancer Agents—A Potential Therapeutic Strategy in Cancer Diseases: Perspectives for Quinazoline Derivatives

  2022cites this paper
• Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation

  2022cites this paper
• Protein Lysine Methyltransferases Inhibitors.

  2022cites this paper
• Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2

  2022cites this paper
• Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.

  2022cites this paper
• Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.

  2022cites this paper
• Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.

  2021cites this paper
• Chemogenomics for drug discovery: clinical molecules from open access chemical probes

  2021cites this paper
• Activity Comparison of Epigenetic Modulators against the Hemoprotozoan Parasites Babesia divergens and Plasmodium falciparum.

  2021cites this paper
• Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design

  2021cites this paper
• Control of Breast Cancer Pathogenesis by Histone Methylation and the Hairless Histone Demethylase

  2021influential citation
• Lysine methyltransferase inhibitors: where we are now

  2021cites this paper
• Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a

  2021cites this paper
• Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.

  2021cites this paper
• Seven-membered rings

  2021cites this paper
• Anticancer activity of pyrimidodiazepines based on 2-chloro-4-anilinoquinazoline: synthesis, DNA binding and molecular docking

  2021cites this paper
• Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.

  2020cites this paper
• Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases

  2020cites this paper
• Targeting EHMT2/ G9a for cancer therapy: progress and perspective.

  2020cites this paper
• Modulating Epigenetic Modification Enzymes Through Relevant Epidrugs as a Timely Strategy in Anticancer Therapy

  2020cites this paper
• Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

  2020cites this paper
• Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulators

  2020cites this paper
• Activity of epigenetic inhibitors against Babesia divergens

  2020cites this paper
• Epigenetic Proteins as Emerging Drug Targets

  2020cites this paper
• Computer‐based Lead Identification for Epigenetic Targets

  2019cites this paper
• Insights for the design of protein lysine methyltransferase G9a inhibitors.

  2019cites this paper
• Chemical Strategies for Evaluating New Drug Targets

  2019cites this paper
• Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.

  2019cites this paper
• Quinazolines as inhibitors of chromatin-associated proteins in histones

  2019cites this paper
• Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma Therapy.

  2019cites this paper
• Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.

  2019cites this paper
• Structure-Based Design of Epigenetic Inhibitors

  2019cites this paper
• Identification of novel quinazoline derivatives as potent antiplasmodial agents.

  2019cites this paper
• Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.

  2019cites this paper
• Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.

  2019cites this paper
• Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor

  2019influential citation
• Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.

  2019cites this paper
• Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.

  2019cites this paper
• G9a and G9a-Like Histone Methyltransferases and Their Effect on Cell Phenotype, Embryonic Development, and Human Disease

  2019cites this paper
• SETting up Methylation in Mammalian Cells: Role of Histone Methyltransferases in Disease and Development

  2018cites this paper
• SMALL MOLECULE INHIBITORS OF G9a AND HDAC FOR TARGETED CANCER THERAPY AND DNA ENCODED GLYCAN LIBRARY (DEGL) FOR EARLY DETECTION OF CANCER

  2018cites this paper
• Target Identification Using Chemical Probes.

  2018cites this paper
• Recent Advances in Chemical Tools for the Regulation and Study of Protein Lysine Methyltransferases.

  2018cites this paper
• Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study

  2018cites this paper
• Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.

  2018cites this paper
• Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening

  2018cites this paper
• Identification of a peptide inhibitor for the histone methyltransferase WHSC1

  2018cites this paper
• Gene and Cell Therapy: Biology and Applications

  2018cites this paper
• Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins

  2018cites this paper
• Preliminary investigations into the synthesis and antimicrobial activities of boron-containing capsaicinoids

  2018cites this paper
• Activity-guided development of potent and selective toll-like receptor 9 antagonists.

  2018cites this paper
• Methyllysine binding domains: Structural insight and small molecule probe development.

  2017cites this paper
• COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS CROSS-REFERENCE TO RELATED APPLICATIONS

  2017cites this paper
• An insight into the therapeutic potential of quinazoline derivatives as anticancer agents.

  2017cites this paper
• Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.

  2017cites this paper
• Misregulation of Histone Methylation Regulators in Cancer

  2017cites this paper
• Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

  2017cites this paper
• In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level

  2017cites this paper
• An alternative synthesis of Vandetanib (Caprelsa™) via a microwave accelerated Dimroth rearrangement

  2017cites this paper
• Inhibitors of Epigenetic Regulation in Cancer

  2017cites this paper
• Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity

  2017cites this paper
• Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors

  2017cites this paper
• Targeting human SET1/MLL family of proteins

  2017cites this paper
• Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.

  2017cites this paper
• Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells.

  2017cites this paper
• Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models

  2017influential citation
• A chemical probe toolbox for dissecting the cancer epigenome

  2017cites this paper
• DNA and Histone Methylation as Cancer Targets

  2017influential citation